BioMarin Pharmaceutical Beheer
Beheer criteriumcontroles 2/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Alexander Hardy
Algemeen directeur
US$18.6m
Totale compensatie
| Percentage CEO-salaris | 0.3% |
| Dienstverband CEO | less than a year |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | 3.1yrs |
| Gemiddelde ambtstermijn bestuur | 5.3yrs |
Recente managementupdates
Recent updates
Biomarin: Challanges Mount, But Sale Rumours Make For A Risky "Buy" Call
Nov 21BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Not Flying Under The Radar
Nov 14
BioMarin Pharmaceutical (NASDAQ:BMRN) Seems To Use Debt Rather Sparingly
Sep 21BioMarin: Voxzogo Sales Surge Isn't Only Driving Force In 2024
Aug 21BioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal In 09/2024
Jul 24An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 46% Undervalued
Jun 01BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain
May 15Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Apr 26BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shares Lagging The Industry But So Is The Business
Apr 21Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Mar 30BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth
Feb 29BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest?
Jan 19Little Excitement Around BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Revenues
Jan 05Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 49% Discount?
Dec 15Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Nov 03Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 42% Discount?
Aug 09We Think BioMarin Pharmaceutical (NASDAQ:BMRN) Can Stay On Top Of Its Debt
Jul 18BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Could Be 42% Below Their Intrinsic Value Estimate
May 09Why Investors Shouldn't Be Surprised By BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Low P/S
Apr 18These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely
Mar 27An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 39% Undervalued
Jan 09BioMarin redesigns organization, will lay off about 4% of its workforce
Oct 07BioMarin resubmits biologics license application to FDA for hemophilia A gene therapy
Sep 29BioMarin touts report on cost effectiveness of gene therapy Roctavian for hemophilia A
Sep 15BioMarin to resubmit hemophilia therapy for FDA approval after EU nod
Aug 25BioMarin may be an activist target after 13-F filings
Aug 15BioMarin (BMRN) boosts 2022 top and bottom line guidance on back of product sales growth
Aug 03BioMarin: More Growth
Jul 21BioMarin's Solid Pipeline Bears The First Fruit
Jun 27Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$322m |
| Jun 30 2024 | n/a | n/a | US$257m |
| Mar 31 2024 | n/a | n/a | US$205m |
| Dec 31 2023 | US$19m | US$65k | US$168m |
Compensatie versus markt: De totale vergoeding ($USD 18.59M ) Alexander } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.66M ).
Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Alexander te vergelijken met de prestaties van het bedrijf.
CEO
Alexander Hardy (55 yo)
less than a year
Tenure
US$18,586,001
Compensatie
Mr. Alexander Hardy serves as President, Chief Executive Officer & Director of BioMarin Pharmaceutical Inc. since December 01, 2023. He had been Chief Executive Officer at Genentech, Inc. since March 1, 20...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | less than a year | US$18.59m | geen gegevens | |
| CFO & Executive VP | 4.8yrs | US$4.85m | 0.038% $ 4.6m | |
| Executive VP & CTO | no data | US$5.70m | 0.012% $ 1.5m | |
| Advisor | 8.1yrs | US$9.66m | 0.097% $ 11.9m | |
| Group VP & Chief Accounting Officer | 2.5yrs | geen gegevens | 0.00071% $ 87.0k | |
| Chief Scientific Officer & Senior VP of Research and Early Development | no data | geen gegevens | geen gegevens | |
| Group Vice President of Investor Relations | no data | geen gegevens | geen gegevens | |
| Executive VP | 20.8yrs | US$5.19m | 0.029% $ 3.6m | |
| Senior VP & Chief Marketing Officer | 2.5yrs | geen gegevens | geen gegevens | |
| Executive VP & Chief People Officer | 5.8yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Technical Development | 3.1yrs | geen gegevens | geen gegevens | |
| Executive VP & Chief Corporate Affairs Officer | less than a year | geen gegevens | geen gegevens |
3.1yrs
Gemiddelde duur
54yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van BMRN wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.1 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | less than a year | US$18.59m | geen gegevens | |
| Independent Chairman of the Board | 17.9yrs | US$515.44k | 0.060% $ 7.3m | |
| Independent Director | 8.8yrs | US$470.44k | 0.021% $ 2.6m | |
| Independent Director | less than a year | US$213.38k | geen gegevens | |
| Independent Director | 22.3yrs | US$486.44k | 0.049% $ 6.0m | |
| Independent Director | 8.3yrs | US$480.44k | 0.012% $ 1.5m | |
| Independent Director | 3.8yrs | US$473.94k | 0.0065% $ 799.7k | |
| Independent Director | 7.2yrs | US$486.94k | 0.014% $ 1.7m | |
| Independent Director | less than a year | US$213.38k | geen gegevens | |
| Independent Director | 5.3yrs | US$480.44k | 0.0099% $ 1.2m | |
| Independent Director | less than a year | US$213.38k | geen gegevens |
5.3yrs
Gemiddelde duur
64yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van BMRN wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.3 jaar).